Results 51 to 60 of about 117 (84)

The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response. [PDF]

PLoS Neglected Tropical Diseases, 2015
Dengue is the most prevalent mosquito-borne viral disease worldwide. Yet, there are no vaccines or specific antivirals available to prevent or treat the disease. Several dengue vaccines are currently in clinical or preclinical stages.
Jacky Flipse, Jolanda M Smit
doaj   +1 more source

Global health concern on the rising dengue and chikungunya cases in the American regions: Countermeasures and preparedness

Health Science Reports, Volume 7, Issue 1, January 2024.
Abstract Background and Aim Severe morbidity and mortality due to seasonal infectious diseases are common global public health issues. Vector‐borne viral illnesses like dengue and chikungunya overload the healthcare systems leading to critical financial burden to manage them.
Ranjan K. Mohapatra, Priyadarshini Bhattacharjee, Dhruv N. Desai, Venkataramana Kandi, Ashish K. Sarangi, Snehasish Mishra, Ranjit Sah, Amani Ahmed AL. Ibrahim, Ali A. Rabaan, Kudrat E. Zahan   +9 more
wiley   +1 more source

Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease.

PLoS ONE, 2018
OBJECTIVE:To evaluate the association of rainy season with overall dengue disease incidence and with the efficacy of the Sanofi Pasteur recombinant, live, attenuated, tetravalent vaccine (CYD-TDV) in two randomized, controlled multicenter phase III ...
Chloé Pasin, M Elizabeth Halloran, Peter B Gilbert, Edith Langevin, R Leon Ochiai, Punnee Pitisuttithum, Maria Rosario Capeding, Gabriel Carrasquilla, Carina Frago, Margarita Cortés, Laurent Chambonneau, Zoe Moodie   +11 more
doaj   +1 more source

Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure.

PLoS Neglected Tropical Diseases, 2019
The tetravalent dengue vaccine CYD-TDV (Dengvaxia) is the first licensed vaccine against dengue, but recent findings indicate an elevated risk of severe disease among vaccinees without prior dengue virus (DENV) exposure.
Guido España, Yutong Yao, Kathryn B Anderson, Meagan C Fitzpatrick, David L Smith, Amy C Morrison, Annelies Wilder-Smith, Thomas W Scott, T Alex Perkins   +8 more
doaj   +1 more source

Multi-walled carbon nanotubes functionalized with recombinant Dengue virus 3 envelope proteins induce significant and specific immune responses in mice

Journal of Nanobiotechnology, 2017
Background Dengue is the most prevalent arthropod-borne viral disease in the world. In this article we present results on the development, characterization and immunogenic evaluation of an alternative vaccine candidate against Dengue.
Alice F. Versiani, Ruiz G. Astigarraga, Eliseu S. O. Rocha, Ana Paula M. Barboza, Erna G. Kroon, Milene A. Rachid, Daniele G. Souza, Luiz O. Ladeira, Edel F. Barbosa-Stancioli, Ado Jorio, Flávio G. Da Fonseca   +10 more
doaj   +1 more source

Targeting vaccinations for the licensed dengue vaccine: Considerations for serosurvey design.

PLoS ONE, 2018
BackgroundThe CYD-TDV vaccine was unusual in that the recommended target population for vaccination was originally defined not only by age, but also by transmission setting as defined by seroprevalence.
Natsuko Imai, Neil M Ferguson
doaj   +1 more source

Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia®) in the state of Paraná, Brazil: integrating case-cohort and case-control designsResearch in context

The Lancet Regional Health. Americas
Summary: Background: CYD-TDV (Dengvaxia®) was the first dengue vaccine approved, launched in Brazil in 2015 for individuals aged 9–44 years. We aimed to estimate the effectiveness of CYD-TDV in preventing symptomatic dengue cases during a campaign ...
Fredi Alexander Diaz-Quijano, Denise Siqueira de Carvalho, Sonia Mara Raboni, Silvia Emiko Shimakura, Angela Maron de Mello, Magda Clara Vieira da Costa-Ribeiro, Lineu Silva, Marilene da Cruz Magalhães Buffon, Eliane Mara Cesario Pereira Maluf, Gabriel Graeff, Gustavo Almeida, Clara Preto, Karin Regina Luhm   +12 more
doaj   +1 more source

Vaccines licensed and in clinical trials for the prevention of dengue

Human Vaccines & Immunotherapeutics, 2017
Dengue has become a major global public health threat with almost half of the world's population living in at-risk areas. Vaccination would likely represent an effective strategy for the management of dengue disease in endemic regions, however to date ...
J. Torresi, G. Ebert, M. Pellegrini
doaj   +1 more source

Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico´s Universal Vaccination Program

Salud Pública de México, 2016
Dengue is a major global public health problem affecting Latin America and Mexico Prevention and control measures, focusing on epidemiological surveillance and vector control, have been partially effective and costly, thus, the development of a vaccine ...
Mauricio Hernández-Ávila, José Ignacio Santos-Preciado   +1 more
doaj  

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy

eLife, 2017
This study defined the genetic epidemiology of dengue viruses (DENV) in two pivotal phase III trials of the tetravalent dengue vaccine, CYD-TDV, and thereby enabled virus genotype-specific estimates of vaccine efficacy (VE).
Maia A Rabaa, Yves Girerd-Chambaz, Kien Duong Thi Hue, Trung Vu Tuan, Bridget Wills, Matthew Bonaparte, Diane van der Vliet, Edith Langevin, Margarita Cortes, Betzana Zambrano, Corinne Dunod, Anh Wartel-Tram, Nicholas Jackson, Cameron P Simmons   +13 more
doaj   +1 more source